tiprankstipranks
Trending News
More News >

Protagonist Therapeutics initiated with a Buy at Citi

Citi analyst Geoff Meacham initiated coverage of Protagonist Therapeutics (PTGX) with a Buy rating and $72 price target The firm cites the potential of rusfertide in polycythemia vera and oral IL-23 in multi-billion inflammation indications for the Buy rating. Citi acknowledges the share outperformance over past three months, but believes rusfertide’s “impressive efficacy” as demonstrated in Phase 3, including improvement in quality of life scores, suggests the drug has “strong potential” in polycythemia vera patients as despite therapeutic advancement there still remains unmet need.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1